| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1797 | |
| Phytochemical name or plant extracts | Artemisia Keiskeana extract (AKE) | |
| PMID | 23596819 | |
| Literature evidence | Antiobesity activity was showed with reducing lipid accumulation significantly (> 50%) at concentrations above 100 mg/mL in most extracts (except AST and ACA). | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Methanolic extract | |
| Source of phytochemicals or plant Extracts | Artemisia Keiskeana | |
| Geographical availability | China North-Central, Japan, Korea, Manchuria, Primorye | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | NA | |
| Cell line/ mice model | HS578T, T47D | |
| Additional information | Although extracts at lower concentrations and shorter times stimulated growth of T47D cells, the antiproliferative effects of the extracts on T47D cells at higher concentrations (> 100 mg/ mL) for 72 h were significantly greater than those of HS578T cells. In case of anti-inflammatory activity, some extracts (AST, ASE, ACA, and AKE) significantly reduced nitric oxide production at higher concentrations in the presence of LPS compared with that in control cells. Antiobesity activity was showed with reducing lipid accumulation significantly (> 50%) at concentrations above 100 mg/mL in most extracts (except AST and ACA). Additionally, AKE and ASC increased lipolysis by 11%-24% compared with that in the control. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:179677-1 | |
| Safety | NA |